Akebia And CSL Vifor Have Terminated The License Agreement Providing For The Payment Of Royalties By Akebia To CSL Vifor On Vafseo (Vadadustat) U.S. Net Product Sales. As A Result, Akebia Regained Full Rights To Sell Vafseo In The U.S.
Akebia And CSL Vifor Have Terminated The License Agreement Providing For The Payment Of Royalties By Akebia To CSL Vifor On Vafseo (Vadadustat) U.S. Net Product Sales. As A Result, Akebia Regained Full Rights To Sell Vafseo In The U.S.
阿克必治和CSL Vifor已终止许可协议，不再需要阿克必治向CSL Vifor支付Vafseo（Vadadustat）美国净销售产品销售额的版税。因此，阿克必治重新获得了在美国销售Vafseo的所有权。
- Under the terms of the agreement, CSL Vifor is entitled to quarterly tiered royalty payments ranging from a high single-digit percentage on annual net sales up to $450 million to a mid-single digit percentage on annual net sales above $450 million. Akebia has the opportunity to buy down the royalty agreement beginning on July 1, 2027 with a one-time payment to CSL Vifor, which would decrease the royalty payments to a mid-single digit percentage of Akebia's annual net sales of Vafseo up to $450 million and eliminate the royalty payment on annual net sales above $450 million.
- Announced Vafseo WAC pricing of $1,278 for a 30-day supply
- Submitted TDAPA application for Vafseo in June 2024 and expects designation on January 1, 2025
- 按照协议，CSL Vifor有权获得季度分层版税支付，范围从年销售净额高达$45000万的高个位数百分比到年销售净额超过$45000万的中个位数百分比。Akebia有机会在2027年7月1日开始通过向CSL Vifor一次性支付购买版税协议的方式来降低版税支付费用，这将把版税支付降至Akebia的Vafseo年销售净额45000万美元以下的中个位数百分比，并消除年销售净额超过45000万美元的版税支付。
- 宣布Vafseo 30天供应的WAC定价为$1,278
- 于2024年6月提交了Vafseo的TDAPA申请，并期望在2025年1月1日获得指定。